
Merck Keytruda Win, Madrigal $4.4B Deal, Jobs Report Surprise — First Immunotherapy for Platinum-Resistant Ovarian Cancer, Viking Confirms Phase 3 Timeline, Healthcare Adds 82K Jobs
Merck has secured a pivotal first-mover advantage with the dual FDA approval of IV and subcutaneous Keytruda in platinum-resistant ovarian cancer, effectively building a defensive








